v::RET
About
Gene context: RET
Biomarker Type: Rearrangement
Present: True
Rearrangement Type: Fusion
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::RET | Non-Small Cell Lung Cancer | Pralsetinib | FDA |
| Sensitivity (+) | v::RET | Papillary Thyroid Cancer | Pralsetinib | FDA |
| Sensitivity (+) | v::RET | Non-Small Cell Lung Cancer | Selpercatinib | HC |
| Sensitivity (+) | v::RET | Papillary Thyroid Cancer | Selpercatinib | HC |
| Sensitivity (+) | v::RET | Non-Small Cell Lung Cancer | Selpercatinib | FDA |
| Sensitivity (+) | v::RET | Anaplastic Thyroid Cancer | Selpercatinib | FDA |
| Sensitivity (+) | v::RET | Any solid tumor | Selpercatinib | FDA |